RBC Capital Reiterates Outperform on Edgewise Therapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $28 price target.
March 12, 2024 | 3:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Leonid Timashev reaffirmed an Outperform rating on Edgewise Therapeutics with a $28 price target.
The reiteration of an Outperform rating and maintenance of a $28 price target by a reputable analyst like Leonid Timashev suggests a strong vote of confidence in Edgewise Therapeutics. This endorsement is likely to positively influence investor sentiment and could lead to a short-term uptick in EWTX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100